FDA Approved Products
1,302 products with lifecycle intelligence, competitive pressure scores, and patent timelines.
CAROSPIR
spironolactone
Peak
ORAL · SUSPENSION
NYHA Class III-IV heart failurereduced ejection fraction in adult patients to increase survival+10
2017
NDA0/100
CASPOFUNGIN ACETATE
caspofungin acetate
Peak
Fresenius Kabi
INTRAVENOUS · POWDER
the following Candida infections: intra-abdominal abscessesperitonitis+8
2016
NDA0/100
CEQUA
cyclosporine
Peak
Fosun Pharma
OPHTHALMIC · SOLUTION
2018
NDA0/100
CERDELGA
eliglustat
Peak
Sanofi
ORAL · CAPSULE
2014
SMNDA0/100
CETYLEV
acetylcysteine
Peak
R-Pharm US
ORAL · TABLET, EFFERVESCENT
lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in adultsgreater with acute ingestion+1
2016
NDA0/100
CIBINQO
abrocitinib
Peak
Pfizer
ORAL · TABLET
2022
SMNDA0/100
CINVANTI
aprepitant
Peak
Heron Therapeutics
INTRAVENOUS · EMULSION
delayed nauseavomiting associated with initial+3
2017
NDA0/100
CLENPIQ
sodium picosulfate, magnesium oxide, and anhydrous citric acid
Peak
Ferring Pharmaceuticals
ORAL · SOLUTION
2017
NDA0/100
CLEVIPREX
clevidipine
Peak
Chiesi
INTRAVENOUS · EMULSION
blood pressurenot desirable
2008
SMNDA0/100
CLOROTEKAL
chloroprocaine hydrochloride
Peak
B. Braun
INTRATHECAL · SOLUTION
2017
NDA0/100
COMBOGESIC
acetaminophen and ibuprofen
Peak
ORAL · TABLET
2023
SMNDA0/100
COMETRIQ
cabozantinib
Peak
Exelixis
ORAL · CAPSULE
metastatic medullary thyroid cancer (MTC)
2012
SMNDA0/100
COMPLERA
emtricitabine, rilpivirine hydrochloride, and tenofovir disoproxil fumarate
Peak
Gilead Sciences
ORAL · TABLET
2011
NDA0/100
CONSENSI
amlodipine besylate; celecoxib
Peak
Purple Biotech
ORAL · TABLET
hypertensionto lower blood pressure+5
2018
SMNDA0/100
CONTRAVE
naltrexone hydrochloride and bupropion hydrochloride
Peak
ORAL · TABLET, EXTENDED RELEASE
combination with a reduced-calorie dietincreased physical activity to reduce excess body weight+2
2014
NDA0/100
COPIKTRA
duvelisib
Peak
Secura Bio
ORAL · CAPSULE
refractory chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL) after at least two prior lines lines of systemic therapy+2
2018
SMNDA0/100
COSELA
trilaciclib
Peak
Pharmacosmos
INTRAVENOUS · POWDER
chemotherapy-induced myelosuppression in adult patientstopotecan-containing regimen for extensive-stage small cell lung cancer+1
2021
SMNDA0/100
COTELLIC
cobimetinib
Peak
Roche
ORAL · TABLET
metastatic melanoma with a BRAF V600EV600K mutation+2
2015
SMNDA0/100
COTEMPLA XR-ODT
methylphenidate
Peak
Therapeutic Solutions International
ORAL · TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE
Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age
2017
NDA0/100
CUVRIOR
trientine tetrahydrochloride
Peak
Orphalan
ORAL · TABLET
tolerant to penicillamine
2022
NDA0/100
CYCLOPHOSPHAMIDE
cyclophosphamide
Peak
Dr. Reddy's Laboratories
INTRAVENOUS · SOLUTION
IV of the Ann Arbor staging system)Hodgkin's disease+13
2020
NDA0/100
CYCLOPHOSPHAMIDE
cyclophosphamide
Peak
INTRAVENOUS · SOLUTION
lymphocytic lymphomamixed-cell type lymphoma+5
2021
NDA0/100
CYCLOSET
bromocriptine mesylate
Peak
ORAL · TABLET
type 2 diabetes mellitustype 1 diabetes+1
2009
NDA0/100
CYSVIEW KIT
hexaminolevulinate hydrochloride
Peak
INTRAVESICAL · FOR SOLUTION
2010
NDA0/100